Maxwellia gets funds to transform switching
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
An injection of venture capital will help transform switch specialist Maxwellia into a pioneering “research and development (R&D) engine” for the European OTC industry, according to the firm’s chief executive officer Anna Maxwell.